Novartis granted US FDA Priority Review for Kymriah™ (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL

January 16, 2018

Responsive image

EAST HANOVER, N.J., Jan. 17, 2018 /PRNewswire/ — Novartis today announced that its supplemental Biologics License Application (sBLA) for Kymriah™ (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, for the treatment of adult patients with relapsed or refractory (r/r)…

Category: Precious Metals